Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD56 inhibitors(Neural cell adhesion molecule 1 inhibitors), GD2 inhibitors(Disialoganglioside GD2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma | Phase 2 | China | 01 Jun 2026 | |
| Hematologic Neoplasms | Phase 2 | China | 01 Jun 2026 | |
| Nervous System Neoplasms | Phase 2 | China | 01 Jun 2026 | |
| Neuroblastoma | Phase 2 | China | 01 Jun 2026 | |
| Refractory Cancer | Phase 2 | China | 01 Jun 2026 | |
| Small Cell Lung Cancer | Phase 2 | China | 01 Jun 2026 |





